Protect Women's Health and Prevent Cervical Cancer
The HPV vaccine series products independently developed by Wantai Biopharm adopt innovative prokaryotic expression technology in Escherichia coli, providing safe, effective and economical solutions for the prevention of cervical cancer, and comprehensively upgrading the defense line against cervical diseases.
Core Advantages
Highly Effective Prevention
The protection rate against high-grade precancerous lesions related to HPV 16/18 types reaches 100%, and the protection rate against persistent infection for 6 months is as high as 97.7%.
Economical and Affordable
With a relatively low product price, it enables more women to obtain effective protection against cervical cancer.
International Certification
It passed the WHO Prequalification and became the first Chinese HPV vaccine product to be PQed, marking that the safety, effectiveness and quality of the product have been recognized by the WHO. This allowed Cecolin® to officially entered the procurement list of the United Nations vaccine procurement agencies.
Wide Applicability
Women aged 9 to 45 can be vaccinated, and women aged 9 to 14 only need to receive two doses of vaccination.
Research and Development Process
Important milestones from scientific research and development to emergency use authorization.
2019
The first Chinese HPV vaccine was approved by the National Medical Products Administration, making China the third country in the world, after the United States and the United Kingdom, to achieve independent supply of HPV vaccines. It was selected as one of the “Top Ten Advances in Chinese Medical Biotechnology”.
2021
It passed the WHO PQ certification and became the first Chinese HPV vaccine product to be certified, marking that the safety, effectiveness and quality of the product have been recognized by the WHO. Cecolin® officially entered the procurement list of the United Nations vaccine procurement agencies.
2022
The verification of the workshop facilities for the 9-valent HPV vaccine was completed, preparing for the launch of the new generation of products.
2023
The research, development and application of the recombinant human papillomavirus types 16/18 bivalent vaccine (Escherichia coli) won the first prize of the Xiamen Science and Technology Award; the truncated human papillomavirus type 16 L1 protein won the Special Award of the 9th Xiamen Patent Award.
2024
By the end of 2024, it had obtained marketing licenses in more than 20 countries, and the achievements of Chinese scientific and technological innovation benefited the countries along the Belt and Road Initiative.
HPV Vaccine Product Series
Bivalent HPV Vaccine
Bivalent human papillomavirus vaccine (HPV 16&18) is used to prevent cervical cancer and precancerous lesions caused by HPV 16 and 18 infections. It took 16 years to develop, with a cumulative investment of nearly 800 million yuan, and has multiple international certifications and honors.
- Aiming at HPV 16/18 types, these two high-risk types of viruses are the main causes of cervical cancer.
- Women aged 9 to 14 only need to receive two doses of vaccination, simplifying the vaccination procedure.
- The protection rate reaches 100%, and the protection rate against persistent infection for 6 months is as high as 97.7%.
- Wide applicable age range: women aged 9 to 45.
9-valent HPV Vaccine
The 9-valent human papillomavirus vaccine, compared with the bivalent vaccine, adds protection against infections of five high-risk types 31, 33, 45, 52 and 58, as well as two low-risk types of HPV 6 and 11, providing a more comprehensive preventive effect against cervical cancer.
- Prevent infections of 9 types of HPV, covering a broader spectrum of virus types.
- At the same time, it prevents condyloma acuminata caused by low-risk HPV 6 and 11.
- It has independent intellectual property rights for 9 types.
- It is supported by the 863 Project of the Ministry of Science and Technology of China.
For more information : wtexport@ystwt.com
Filing Number:（京）网药械信息备字（2023）第00164号
Copyright©Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
|
|
京公网安备11011402010353号 
Alibaba Cloud provides cloud computing and security services.|
It supports
|
Powered by CloudDream
|
Terms Of Use|
Privacy Statement